Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211

Разработка средств ядерной медицины, селективных к LAT1, с использованием астата-211
Tadashi Watabe, Yoshikatsu Kanai, Kazuko Kaneda‐Nakashima, Kazuhiro Ooe, Atsushi Toyoshima, Hiromitsu Haba, Masashi Murakami, Atsushi Shimoyama, Koichi Fukase, Yoshifumi Shirakami, Kentaro Hisada, Sifan Feng, Yuichiro Kadonaga, Yoshiyuki Manabe
2024-11-18

3-[211At]astato-α-methyl-L-tyrosineLAT1-targeted therapeuticsalpha-emitting radionuclideastatine-211nuclear medicine therapy
We investigated nuclear medicine therapeutics targeting the L-type amino acid transporter 1 (LAT1). We previously reported that a nuclear medicine therapeutic drug using astatine 211 (211At), an alpha-emitting nuclide that can be produced in an accelerator and targets LAT1 as a molecular target, is effective. The seed compound was 3-[211At] Astato-α-methyl-L-tyrosine (211At-AAMT-OH-L). We used a unique labeling method. By changing the OH group of phenol to a methyl group, retention was successfully increased. It was also found that the amount of the L-isomer taken up by the D-isomer and L-isomer was clearly higher, and the L-isomer was superior as a therapeutic drug. Compounds in which the methyl group was replaced with an ethyl or propyl group were also examined, but their retention did not increase significantly. In fact, we observed increased non-specific accumulation and dynamics, suggesting that labeling may be off. In addition, 211At-AAMT-O-Me-L, which has a simple structure, was clearly superior in terms of uptake speed for several candidate compounds. As a result, we were able to develop a compound that can be easily labeled, has high specific radioactivity, is stable, and has a strong therapeutic effect.
1
Astatine-211-labeled LAT1-targeting compounds were investigated as alpha-emitting nuclear medicine therapeutics.
2
Methylating the phenolic OH group increased compound retention compared with the seed compound 211At-AAMT-OH-L.
3
Replacing the methyl group with ethyl or propyl did not significantly improve retention and increased nonspecific accumulation, suggesting possible labeling problems.
4
The L-isomer showed clearly higher uptake than the D-isomer and was superior for therapeutic development.
5
The simple 211At-AAMT-O-Me-L structure showed superior uptake speed and enabled development of a readily labeled, highly specific, stable compound with strong therapeutic effects.

LAT1-targeting astatine-211 nuclear medicine therapeutic compounds, particularly 211At-AAMT-O-Me-L

The effects of structural modifications and stereochemistry on LAT1 uptake, retention, specificity, labeling properties, stability, and therapeutic performance

Publication Details
Publication Date
2024-11-18
Journal
Publisher
ISSN
Cited by
7
Access Type
Author Information
Authors
Tadashi Watabe
Yoshikatsu Kanai
Kazuko Kaneda‐Nakashima
Kazuhiro Ooe
Atsushi Toyoshima
Hiromitsu Haba
Masashi Murakami
Atsushi Shimoyama
Koichi Fukase
Yoshifumi Shirakami
Kentaro Hisada
Sifan Feng
Yuichiro Kadonaga
Yoshiyuki Manabe
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%